Skip to main content

Cancer Vaccine development for Hepatocellular Carcinoma

Objective

"Hepatocellular carcinoma (HCC) is the most common primary liver cancer and accounts for about 6% of all new cancer cases worldwide. Given the lack of available effective treatments, the overall prognosis for HCC patients is poor, with a dismal 5-year survival of 5-6%. The main goal of this proposal is to develop a therapeutic cancer vaccine aiming at improving clinical outcome in early-stage HCC patients after loco-regional ablative therapy.
HepaVac is an European consortium of academic, SME and pharmaceutical company partners with complementary and substantial expertise in cancer immunotherapy and vaccine development. The main objective of HepaVac is to develop a novel cancer vaccine approach for HCC based on epitopes naturally processed and presented by HLA class I and II (HLA-ligandome), to elicit both CD4+ T helper and CD8+ CTL tumor-specific effector and memory responses. The HCC HLA-ligandome will be identified in primary tumor tissues using a combined and integrated approach, developed and thoroughly validated by Partners #2 and #5. The selected peptide epitopes will constitute the candidate cancer vaccine for HCC, aiming at covering the broadest haplotype diversity with a multi-epitope and multi-TAA strategy. T cell epitopes derived from universal TAA and unique patient-specific mutated antigens will allow the design of a prime-boost vaccine strategy based either on a prime-boost schedule made of an “off-the-shelf” T cell epitope cocktail or on a schedule where the boost is complemented by a “personalized” T cell epitope cocktail. Both epitope cocktails will be adjuvanted in a novel and potent immunomodulator developed by Partner #6. Such a vaccination strategy will be tested in a randomized controlled multi-center phase I/II human clinical trial, assessing as primary endpoints safety and induction of specific cellular immune responses and, as secondary endpoints, OS and PFS of patients receiving the vaccine after tumor ablation vs tumor ablation alone."

Field of science

  • /medical and health sciences/basic medicine/immunology/immunotherapy
  • /medical and health sciences/clinical medicine/oncology/cancer
  • /medical and health sciences/clinical medicine/oncology/cancer/liver cancer

Call for proposal

FP7-HEALTH-2013-INNOVATION-1
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

ISTITUTO NAZIONALE TUMORI Fondazione Pascale
Address
Via Mariano Semmola 142
80131 Napoli
Italy
Activity type
Research Organisations
EU contribution
€ 1 845 500
Administrative Contact
Vincenza Farinari (Dr.)

Participants (9)

EBERHARD KARLS UNIVERSITAET TUEBINGEN
Germany
EU contribution
€ 700 840
Address
Geschwister-scholl-platz
72074 Tuebingen
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Hans-Georg Rammensee (Prof.)
UNIVERSITA DEGLI STUDI DELL'INSUBRIA
Italy
EU contribution
€ 410 796,80
Address
Via Ravasi 2
21100 Varese
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Roberto Accolla (Prof.)
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

Participation ended

France
EU contribution
€ 264 084,12
Address
Rue De Tolbiac 101
75654 Paris
Activity type
Research Organisations
Administrative Contact
Danila Valmori (Prof.)
IMMATICS BIOTECHNOLOGIES GMBH
Germany
EU contribution
€ 1 934 200
Address
Paul Ehrlich Str 15
72076 Tuebingen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Maria Poulada
CUREVAC GMBH
Germany
EU contribution
€ 312 540
Address
Paul Ehrlich Strasse 15
72076 Tuebingen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Oliver Schlüter (Dr.)
THE UNIVERSITY OF BIRMINGHAM
United Kingdom
EU contribution
€ 254 914
Address
Edgbaston
B15 2TT Birmingham
Activity type
Higher or Secondary Education Establishments
Administrative Contact
May Chung (Ms.)
UNIVERSIDAD DE NAVARRA
Spain
EU contribution
€ 117 950
Address
Campus Universitario Edificio Central
31080 Pamplona
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Fco. Javier Irigoyen Barrio (Mr.)
UNIVERSITAIR ZIEKENHUIS ANTWERPEN
Belgium
EU contribution
€ 115 850
Address
Wilrijkstraat 10
2650 Edegem
Activity type
Research Organisations
Administrative Contact
Sven Francque (Prof.)
UNIVERSITE DE NANTES
France
EU contribution
€ 39 435,88
Address
Quai De Tourville 1
44035 Nantes Cedex 1
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Clément Michaud